Berenberg raised the firm’s price target on Grifols to EUR 15.45 from EUR 14.85 and keeps a Buy rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRFS:
- Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients
- GRFS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Grifols board votes to grant Brookfield access to information
- Top Stock Gainers Today – LNTH, APGE, and More
- M&A News: Grifols Shoots Up Amid Takeover Bid